ALFA FinderBSE filing, NSE: KPL. Summary written from the filing by ALFA Finder's alert engine.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,942.20
- Market cap
- ₹4,091 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 42.6×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Investor Presentation: Key Takeaways
Q2FY27 revenue ₹181.2 Cr (+62% YoY, +12% QoQ), EBITDA ₹49.8 Cr (27.5% margin), PAT ₹29.0 Cr (16.0%). FY27 revenue guidance raised to ₹720+ Cr.
- Call
- Guides 43% growth
Kwality Pharmaceuticals Q2 FY27 Results: Net Profit ₹29 Cr, Up 105.7% YoY
Kwality Pharmaceuticals Ltd reported revenue from operations of ₹181.2 Cr (+63.1% YoY) and net profit of ₹29 Cr (+105.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹29 Cr · +105.7% YoY
Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Other management change announcements
All →Ruby Mills Management Change
Ruby Mills appointed two directors and a COO, with Rishabh Shah ceasing as President. Changes take effect from 12 to 23 November 2026.
Afcom Holdings Management Change
Afcom Holdings' non-executive director Jaganmohan Manthena resigned effective November 12, 2026, along with all committee roles. The resignation letter citing personal and entrepreneurial priorities is enclosed.
Mehai Technology Management Change
MEHAI Technology's Company Secretary, Mr. Sandipan Lai, resigned for personal reasons, effective November 12, 2026. The change was approved at a board meeting held the same day.
Prakash Pipes Management Change
Prakash Pipes appointed Sachin Ghanghas as Company Secretary, Amitava Ray as Executive Director and Priyanka Agarwal as Independent Director, effective December 1, 2026 for the directors. These are board and KMP appointments with no monetary value.
Gaudium IVF And Women Health Management Change
Gaudium IVF appointed Ravish Manchanda as National Head - Operations Expansion & Strategy, a senior management role. No monetary value or business event is involved.
PTC Industries Management Change
PTC Industries' Non-Executive Independent Director, Rakesh Shukla, resigned effective November 12, 2026, citing personal commitments. The company disclosed the resignation and the letter under Regulation 30.